Equillium (EQ) Convertible Debt (2017 - 2018)
Equillium (EQ) posted quarterly Convertible Debt of $10.3 million for Q3 2018, up 47.56% quarter-over-quarter from $7.0 million in Q4 2017.
Equillium (EQ) Convertible Debt (2017 - 2018) Analysis & Trends
Equillium (EQ) has reported Convertible Debt for 2 consecutive years, with $10.3 million the latest figure, recorded in Q3 2018.
- In Q3 2018, Convertible Debt changed N/A year-over-year to $10.3 million; the TTM figure through Sep 2018 stood at $10.3 million (changed N/A YoY), while the FY2017 annual figure was $7.0 million, changed N/A from the prior year.
- Convertible Debt climbed to $10.3 million in Q3 2018 per EQ's latest filing, from $7.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $10.3 million in Q3 2018 and bottomed at $7.0 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10.32 Mn |
| Dec 31, 2017 | 6.99 Mn |